Our CEO Marcus Claesson was the last author on a joint publication in Immuno Horizons by scientists from SeqBiome, University College Cork and Basel-based Hoffmann-La Roche.
While the contribution of the gut microbiome to the onset of Type 1 diabetes (T1D) is already known, the role of new anti-PD-1 cancer immunotherapies is less clear. The team used a non-obese diabetic mouse model to show that anti–PD-1 treatment and T1D altered both microbiota composition and diversity over time. Insulin-regulating bacteria potentially capable of reducing glucose levels were also identified, including an increase of mucin-degrading Akkermansia muciniphila. To modulate the gut microbiome might thus be a promising approach to mitigate some adverse effects associated with immunotherapies.